Intestinal Microbiota in COPD and Asthma — MicrObAs  

Chronic Respiratory Diseases Clinical Trial

Official title: Identifying the Relationship Between the Features of the Composition and Functioning of the Intestinal Microbiota With the Course of Chronic Obstructive Pulmonary Disease and Asthma (MicrObAs)

Status Completed

Clinical Trial Summary

The composition of the intestinal microbiota, the level of lipopolysaccharides, TMAO in the blood, and other parameters of patients with COPD (n=50), asthma (n=50) and the control (n=40) will be assessed as factors associated with exacerbations and respiratory symptoms in the prospective study (12 months).

Clinical Trial Description

The patients from "Biobank of blood and feces for the development of a clinical and biological platform as a basis for an innovative approach to the prevention of chronic non-infectious diseases based on the composition of the intestinal microbiota" study will be included (cross-sectional study). The protocol of the above study included the assessment of socio-demographic, anthropometric data, clinical blood pressure (BP), ECG, blood tests, fecal microbiota studies, spirometry data, diet questionnaire. ABPM, HBP, other questionnaires (mMRC, CAT, ACQ-5, GMBQ) will be added to initial data (=visit 1). Than the four visits (2-5th visits) in 3 each months will be performed to assess respiratory symptoms, exacerbations of COPD/asthma, respiratory infections, therapy, BP, and other parameters. The standard statistical methods will be used. ;

Related Conditions & MeSH terms

• Chronic Respiratory Diseases
• Respiration Disorders
• Respiratory Tract Diseases

• NCT number: NCT04802317
• Study type: Observational
• Source: National Medical Research Center for Therapy and Preventive Medicine
• Status: Completed
• Start date: June 23, 2020
• Completion date: December 5, 2023